Hematologic Oncology

Omidubicel met the primary end point of time to neutrophil engraftment in patients with high-risk hematologic malignancies undergoing a bone marrow transplant.

Tatyana Feldman, MD, discusses the significance of PET-adapted strategies in Hodgkin lymphoma, novel therapies that have emerged in the pipeline, and where future research is headed.

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

A panel of experts discuss the current and emerging treatment landscape of relapsed/refractory diffuse large B-cell lymphoma.

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the shift toward precision medicine in large cell lymphoma.

Sonali M. Smith, MD, sheds light on some of the recent advances in follicular lymphoma and mantle cell lymphoma, as well as the challenges that remain overall in non-Hodgkin lymphoma.

The FDA has granted an orphan drug designation to HQP1351 for the treatment of patients with chronic myeloid leukemia.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).

The FDA has granted a priority review designation to CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia.

Updated data from the pivotal phase 3 FLASH trial showed that SGX301 (synthetic hypericin) continued to demonstrate strong clinical activity in patients with cutaneous T-cell lymphoma.

A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.

The FDA has approved an updated dosing schedule for pembrolizumab to include an every-6-weeks option at 400 mg across all indications in adult patients.

The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

John N. Allan, MD, discusses the study results of a phase 1b/2 dose-escalation trial with vecabrutinib in patients with B-cell malignancies.

Michael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.

Christopher A. Yasenchak, MD, discusses findings from the phase 2 trial with brentuximab vedotin and nivolumab in patients with newly diagnosed classical Hodgkin lymphoma.

Christopher E. Dandoy, MD, MSc, discusses the clinical features of TA-TMA and the importance of close monitoring and intervention for patients at risk of developing the disorder.

Supplemental biologics license applications have been resubmitted to the FDA for pembrolizumab to include an every-6-weeks option at 400 mg over 30-minute infusions across multiple indications.

The REACH2 ruxolitinib acute graft-versus-host disease data have been published in the New England Journal of Medicine.